XML 149 R19.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Legal Settlements and Loss Contingencies | 12 Months Ended
--- | ---
Dec. 31, 2019
Legal Settlements and Loss Contingencies | NOTE 11—Legal settlements and loss contingencies: Legal settlements and loss contingencies for 2019 amounted to an expense of $1,178 million, compared to an inc ome of $1,208 million and an expense of $500 million in 2018 and 2017, respectively. The expense in 2019 w as mainly related to an estimated provision recorded in connection with settlement of the remaining opioid cases. The 2018 income primarily consisted of the working capital adjustment with Allergan, the Rimsa settlement and reversal of the reserve recorded in the second quarter of 2017 with respect to the carvedilol patent litigation. As of December 31, 2019 and 2018, accrued amounts for legal settlements and loss contingencies of $1,580 million and $562 million, respectively, we re recorded in accrued expenses.

X
- Definition The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI http://asc.fasb.org/topic&trid=2127136 + Details
Name: | us-gaap_LegalMattersAndContingenciesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration